ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Applied Therapeutics
APLT
$73.7M
| $1.5M | 0.28% |
320,727
-135,861
| -30% | -$634K |
|
52
Context Therapeutics
CNTX
$75.6M
| $1.29M | 0.24% |
645,161
+439,227
| +213% | +$881K |
|
53
Astria Therapeutics
ATXS
$394M
| $1.26M | 0.24% |
138,158
+133,506
| +2,870% | +$1.21M |
|
54
iBio
IBIO
$16.9M
| $1.2M | 0.23% |
570,000
-30,000
| -5% | -$63.3K |
|
55
Spero Therapeutics
SPRO
$117M
| $1.19M | 0.23% |
918,929
-8,000
| -0.9% | -$10.4K |
|
56
Indivior
INDV
$3.08B
| $1.13M | 0.21% |
70,007
+42,406
| +154% | +$684K |
|
57
Pfizer
PFE
$141B
| $1.12M | 0.21% |
39,950
-66,392
| -62% | -$1.86M |
|
58
enVVeno Medical
NVNO
$15M
| $1.06M | 0.2% |
201,728
| – | – |
|
59
Target Hospitality
TH
$878M
| $990K | 0.19% |
+113,626
| New | +$990K |
|
60
Guardant Health
GH
$8.11B
| $982K | 0.19% |
34,000
+17,000
| +100% | +$491K |
|
61
Vir Biotechnology
VIR
$765M
| $979K | 0.18% |
+110,000
| New | +$979K |
|
62
Cullinan Oncology
CGEM
$456M
| $929K | 0.18% |
+53,261
| New | +$929K |
|
63
Vaxcyte
PCVX
$4.17B
| $925K | 0.17% |
12,250
+10,250
| +513% | +$774K |
|
|
ITOS
64
DELISTED
iTeos Therapeutics
ITOS
| $890K | 0.17% |
+60,000
| New | +$890K |
|
65
Alector
ALEC
$282M
| $887K | 0.17% |
195,311
+142,811
| +272% | +$648K |
|
66
Denali Therapeutics
DNLI
$2.24B
| $882K | 0.17% |
38,000
+36,000
| +1,800% | +$836K |
|
67
AngioDynamics
ANGO
$432M
| $870K | 0.16% |
143,862
-9,500
| -6% | -$57.5K |
|
68
Arvinas
ARVN
$580M
| $862K | 0.16% |
32,400
+6,200
| +24% | +$165K |
|
69
Spyre Therapeutics
SYRE
$1.02B
| $827K | 0.16% |
35,180
-14,320
| -29% | -$337K |
|
|
AGR
70
DELISTED
Avangrid, Inc.
AGR
| $817K | 0.15% |
+23,000
| New | +$817K |
|
71
Keen Vision Acquisition Corporation Units
KVACU
| $793K | 0.15% |
75,000
| – | – |
|
72
Apellis Pharmaceuticals
APLS
$3.51B
| $792K | 0.15% |
20,650
-5,050
| -20% | -$194K |
|
|
SLN
73
Silence Therapeutics
SLN
$237M
| $766K | 0.14% |
40,290
+200
| +0.5% | +$3.8K |
|
74
Kiora Pharmaceuticals
KPRX
$9.61M
| $725K | 0.14% |
172,596
+50,374
| +41% | +$212K |
|
|
75
Sarepta Therapeutics
SRPT
$1.98B
| $703K | 0.13% |
4,450
-26,655
| -86% | -$4.21M |
|